Homepage Bottom Left
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
David Page: Congratulations on 20 years of service!
Dear David, This is your 20th anniversary with the CHS and we would like to take this time to extend our deepest gratitude for all...
-
All About Mild Hemophilia
Mild hemophilia can be very serious and even life-threatening if injuries or bleeds are not treated promptly and adequately. The past few years, a lot...
-
Has the bleeding disorder world fundamentally changed?
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...
-
Emicizumab rollout well underway
Montreal, December 16, 2021 – The rollout of emicizumab (Hemlibra) in the provinces and territories served by Canadian Blood Services (CBS) is well underway. Emicizumab...